Evidence map›Paper›PMID 35201849›Full record

ArticleJCO precision oncology2022

A Case of Prostate Cancer Harboring Androgen Receptor T878A Progesterone-Responsive Mutant Emerging After Abiraterone Acetate Treatment Responding to Darolutamide.

Andreas Varkaris, Julia Stevens, Yuho Ono, Steven P Balk, Joaquim Bellmunt

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Andreas VarkarisDivision of Hematology-Oncology, Department of Medicine, and Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.ORCID 0000-0001-5776-8844
Julia StevensDivision of Hematology-Oncology, Department of Medicine, and Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.
Yuho OnoDepartment of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School. Boston, MA.ORCID 0000-0003-0312-2161
Steven P BalkDivision of Hematology-Oncology, Department of Medicine, and Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.ORCID 0000-0002-4546-7371
Joaquim BellmuntDivision of Hematology-Oncology, Department of Medicine, and Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.

Funding

Tumor and Circulating Markers as Links Between Obesity and Lethal Prostate CanceP50CA090381 · NCI · DANA-FARBER CANCER INSTITUTE · PI KANTOFF, PHILIP W · 2002 to 2017
$36.2M
Steroid Metabolism in Castration-Resistant Prostate CancerP01CA163227 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI PETER S NELSON · 2013 to 2026
$25.0M
NCI NIH HHS P01 CA163227NCI NIH HHS P50 CA090381
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Prostatic NeoplasmsReceptors, AndrogenAbiraterone AcetateHumansMaleProgesteronePyrazolesAbiraterone AcetatedarolutamideProgesteronePyrazolesReceptors, Androgen

Identifiers

PMID35201849
PMCPMC8974572

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.